He dismissed ongoing turmoil at the agency, noting that he did not make the decisions to lay off thousands of staff at NIH or freeze reviews of grant applications that have essentially put the ...

It is the policy of NIH not to prioritize research activities that focuses gaining scientific knowledge on why individuals ...

At NIH, we are working to optimize our resources to support the best science. By centralizing the peer review process, we will not only reduce costs—we will also improve the quality, consistency ...

At least 24 termination letters have been sent out, according to one official. Several active research grants related to studies involving LGBTQ+ issues, gender identity and diversity, equity and ...

Researchers assessed 3,047 clinical trials that were initiated with industry funding and 1,480 clinical trials initiated with NIH funding from 2015 through 2020.

Pierre Azoulay is an economist and professor at the MIT Sloan School of Management. Weaknesses in NIH’s 70-plus-year-old institutional approaches are increasingly evident. One sign is that ...

A new NIH policy announced last month said research institutions can only seek federal reimbursement of 15% of their indirect costs, which can include scientific computing, heating and cooling ...

Dr. Lawrence Tabak, the former acting director of the National Institutes of Health (NIH) who admitted to Congress last year that his agency funded risky gain-of-function virus research in China ...

The NIH — like most organizations funding scientific research — pays for the direct cost of research, like researchers’ salaries, and indirect costs, like space, equipment, utilities ...

A federal judge in Massachusetts extended the pause on the Trump’s administration’s cuts to NIH funding on Wednesday. The court’s order blocks the NIH from implementing or enforcing their ...

He also served as the agency's top ethics official. An email circulated among NIH staff from Tabak did not explain why he was abruptly stepping down, which multiple people familiar with the ...

In 1972, testicular cancer was a leading killer of young men — almost uniformly fatal. Today, it has a 90 percent survival rate. The drug responsible for this miraculous reversal, Cisplatin ...